3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
1258
Specimen Handling
864
Carboplatin
824
Magnetic Resonance Spectroscopy
806
Cyclophosphamide
798
Cisplatin
719
Nivolumab
660
Paclitaxel
635
Gemcitabine
570
Radiotherapy
570
Biopsy
526
Bevacizumab
467
Dexamethasone
441
fludarabine
403
Docetaxel
375
venetoclax
369
Oxaliplatin
363
Capecitabine
355
Fluorouracil
354
atezolizumab
337
Rituximab
333
durvalumab
332
Doxorubicin
316
Pemetrexed
306
Radiosurgery
304
Drug Therapy
300
Ipilimumab
296
Standard of Care
288
Etoposide
283
Radiation
277
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
anagrelide
×
1 year
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled